Ultimo aggiornamento :
08/05/2024
Farmaco contro il cancro   Dacarbazine  
Iniezione
Stabilità in soluzione Stabilità in miscela Fattori che influenzano la stabilità Compatibilità Metodo di iniezione Bibliografia Pdf
   Struttura chimica  

Nome commerciale   Nome commerciale     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Acocarb Messico
Celdaz India, Perù
Dabaz India
Dacarb India, Perù
Dacarba India
Dacarbaz Turchia
Dacarbazin Austria, Malaysia, Polonia, Ungheria
Dacarbazina Argentina, Chile, Colombia, Ecuador, Spagna
Dacarbazine Australia, Belgio, Canada, Danimarca, Gran Bretagna, India, Iran, Irlanda, Nuova Zelanda, Stati Uniti d’America, Svezia
Dacarex India, Perù
Dacarin India
Dacarpalm Perù
Dacarzine India
Dacatic Finlandia
Dacin Svizzera
Dacmed India
Daracina Colombia
Deticene Arabia Saudita, Francia, Grecia, Italia, Paesi Bassi, Tunisia
Detilem Messico
Detimedac Colombia, Germania
DTI Malaysia
DTIC Australia, Austria, Gran Bretagna, Nuova Zelanda, Stati Uniti d’America, Svezia
Fauldetic Portogallo
Ifadac Messico
Oncocarbil Argentina, Ecuador, Perù
Tiferomed Messico
Bibliografia   Iniezione   Bibliografia : Dacarbazine  
Tipo Pubblicazione
3 Rivista Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
26 Rivista Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL.
Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags.
Am J Health-Syst Pharm 1997 ; 54: 915-920.
40 Rivista Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC.
Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags.
Pharm Sci Communications 1994 ; 4: 97-101.
57 Rivista Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 Rivista Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Rivista Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Rivista Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Rivista Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
184 Rivista Stewart JT, Warren FW, King DT, Fox JL.
Stability of ondansetron hydrochloride and five antineoplasic medications.
Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244 Rivista Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 Rivista Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 Rivista Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Rivista Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307 Rivista Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 Rivista Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Rivista Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
353 Rivista Lunn G, Sansone EB.
Reductive destruction of dacarbazine, procarbazine hydrochloride, isoniazid, and iproniazid.
Am J Hosp Pharm 1987 ; 44: 2519-2524.
492 Rivista Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
860 Rivista Nelson RW, Young R, Lamnin M.
Visual incompatibility of dacarbazine and heparin.
Am J Hosp Pharm 1987 ; 44: 2028.
905 Rivista Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1383 Rivista Stevens MFG, Peatey L.
Photodegradation of solutions of the antitumour drug DTIC.
J Pharm Pharmacol 1978 ; 30: 47P.
1410 Rivista Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1501 Rivista Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121.
1635 Rivista El Aatmani M, Poujol S, Astre C, Malosse F, Pinguet F.
Stability of dacarbazine in amber glass vials and polyvinyl chloride bags.
Am J Health-Syst Pharm 2002 ; 59: 1351-1356.
2107 Rivista Trissel LA, Zhang Y, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration.
Int J Pharm Compound 2006 ; 10: 234-236.
3266 Laboratorio Lipomed Laboratories
Dacarbazine solutions: In Use stability of dacarbazine lipomed®
Lipomed 2011
3267 Laboratorio Lipomed Laboratories
Dacarbazine Lipomed - Summary of Product Characteristics
Lipomed 2011
3540 Laboratorio Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3605 Laboratorio Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit
Lipomed 2010

  Mentions Légales